Hikma Globalizes its Pharmacovigilance Activities

Amman, 28 January 2014 – Hikma Pharmaceuticals (LSE:HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, today announces that it has entered into a new service agreement with PrimeVigilance, a leading international company that provides pharmacovigilance (PV) and medical information services, to gain access to top quality and global-scale PV services.

Press Release Corporate 28 January 2014

Pharmacovigilance or Drug Safety, is the pharmacological science relating to the monitoring, detection and prevention of adverse effects withpharmaceutical products.

This agreement will enable Hikma to globalize all its PV operations across its worldwide group of companies, and assist Hikma in covering all the regulatory and scientific elements of PV required by health authorities in different countries.

In addition, Hikma will better monitor and evaluate the benefit-risk balance of its products, and will be more compliant with the highest standards of quality, international regulations, and codes of best practices. The agreement will also re-enforce Hikma’s commitment to compliance with laws and regulations.

Mr Said Darwazah, Hikma Pharmaceuticals’ CEO said, “I am pleased to announce this partnership with PrimeVigilance, which will enable us to maintain our highest standards of quality. Through this partnership, we fulfill our commitment to the safety of our patients wherever we operate in compliance with all applicable laws and regulations.”

Mr Neil Clark, PrimeVigilance CEO, said “We are very pleased to be working with Hikma and providing a range of important safety services to support their fast-growing, international operations.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.